Cocrystal Pharma, Inc.

Merck Sharp + Dohme Corp.

Cocrystal, Discovery, Inc.

Sam S K Lee

Irina C Jacobson

Michael David Feese

Biing Yuan Lin

Wang Shen

Xiaoling Zheng

Liang Mao

Tianjing Zhao

Hong Xiao

Emiliano J Sanchez

Provided herein are combinations of compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.

Combinations of inhibitors of influenza virus replication

Provided herein are compositions of an antiviral therapeutic to treat influenza suitable for administration via inhalation.

Formulations of influenza therapeutics

Provided herein are compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza. (I)

Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas I-III, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. 

Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection. 

Inhibitors of Hepatitis C virus polymerase

The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R, R, R, and Rare as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

Growing community of inventors

Edmonds, WA, United States of America

Sam S K Lee